Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
01:33am, Friday, 31'st Jul 2026
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
07:06pm, Thursday, 30'th Jul 2026
Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.05 per share a year ago.
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is e
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
09:05am, Thursday, 23'rd Jul 2026
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings con
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
09:05am, Tuesday, 21'st Jul 2026
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
11:51am, Monday, 20'th Jul 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
09:51am, Wednesday, 15'th Jul 2026
Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer
09:05am, Thursday, 02'nd Jul 2026
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
07:51am, Monday, 29'th Jun 2026
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
09:05am, Tuesday, 23'rd Jun 2026
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
11:05am, Tuesday, 09'th Jun 2026
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 04'th Jun 2026
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
09:05am, Tuesday, 02'nd Jun 2026
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa a
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
10:26am, Thursday, 28'th May 2026
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
